Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / CL A
-
Number of holders
-
193
-
Total 13F shares, excl. options
-
24,685,905
-
Shares change
-
+2,446,455
-
Total reported value, excl. options
-
$3,051,928,179
-
Value change
-
+$312,101,188
-
Put/Call ratio
-
257%
-
Number of buys
-
104
-
Number of sells
-
-93
-
Price
-
$123.62
Significant Holders of REATA PHARMACEUTICALS INC - CL A (RETA) as of Q4 2020
238 filings reported holding RETA - REATA PHARMACEUTICALS INC - CL A as of Q4 2020.
REATA PHARMACEUTICALS INC - CL A (RETA) has 193 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24,685,905 shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4,345,724 shares), CPMG Inc (2,896,901 shares), VANGUARD GROUP INC (2,320,031 shares), Invesco Ltd. (1,779,475 shares), FRANKLIN RESOURCES INC (1,461,927 shares), BlackRock Inc. (1,415,513 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,120,922 shares), Duquesne Family Office LLC (749,897 shares), Corriente Advisors, LLC (525,000 shares), and Cormorant Asset Management, LP (500,000 shares).
This table shows the top 193 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.